Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Diabetic Microvascular Dysfunction and Metabolic Stress: Study Summary

Previous related pageVitamin D, Diabetic Microvascular Dysfunction and Metabolic Stress: Full StudyNext related pageVitamin D, Diabetic Microvascular Dysfunction and Metabolic Stress: Full Study
Study at a glance

How was vitamin D studied in diabetes and small blood vessels?

This page compares a study of vitamin D3 in people with type 2 diabetes and nerve damage with a laboratory study of blood-vessel lining cells exposed to high glucose. They examined possible effects on small-vessel function and cell injury. They did not test the same treatment or prove one complete pathway from supplements to prevention of diabetic complications.

What did the vitamin D3 study in people with diabetes report?

Sixty-seven people were assigned to two weekly vitamin D3 doses for 24 weeks, and 62 completed follow-up. The higher-dose group had reported improvements in selected toe-skin blood-flow tests and two immune signals, while several other measured signs of inflammation did not change significantly. Weight and glucose control also improved. There was no placebo group, the way people were assigned to groups was predictable and treatment was known. Inconsistent reporting of some flow results limits precise conclusions.

What did active vitamin D change in cells exposed to high glucose?

Active vitamin D reduced some injury signals and improved survival-related measurements and movement in cells grown in the laboratory. Increasing a protein called TIPE1 opposed several effects. This suggests a possible role for the protein, but does not establish the whole mechanism. The experiment had only three independent repetitions and lacked a control needed to separate glucose-specific effects from other effects of the solution. Computer predictions about receptor binding were not directly confirmed.

Do these findings establish nerve repair or prevention of diabetic complications?

The human study did not measure TIPE1, and the cell experiment did not measure blood flow in a person. A small change in a pain score does not establish a large health benefit or nerve repair. The separate blood-sample comparison was observational, so it could not prove cause and effect. These studies do not establish improved nerve oxygen delivery, prevention of kidney or eye complications, an ideal dose or general treatment safety.

Read the full article below ↓

Two studies examined different parts of the proposed link between vitamin D and diabetic microvascular stress. A human trial reported changes in skin blood-flow measurements and selected inflammatory markers; a laboratory study tested high-glucose injury in endothelial cells. Important design and reporting limitations prevent treating them as proof that vitamin D prevents diabetic complications. For the detailed methods and appraisal, read Vitamin D, Diabetic Microvascular Dysfunction and Metabolic Stress: Full Study.

What the human trial found

Karonova and colleagues allocated 67 people with type 2 diabetes and neuropathy to 5,000 or 40,000 international units of vitamin D3 weekly for 24 weeks. Sixty-two completed follow-up. The even/odd allocation method was predictable, treatment was open label and there was no placebo group. Registration occurred after study completion. These features limit the strength of the treatment comparison.

The higher-dose group showed reported improvement in toe-skin flow indices, lower interleukin-6 and higher interleukin-10, two immune signalling proteins. Several other inflammatory markers did not change significantly. However, the microcirculation table has inconsistent descriptions of variability, and the prose and table disagree about one lower-dose flow result. Precise effect claims require caution.

This is evidence about measured skin microcirculation, not direct oxygen delivery to nerves. Weight and glucose control also improved in the higher-dose group, leaving direct vascular action versus indirect metabolic explanations unresolved. The median pain score changed only from 50 to 47 on a 100-mm scale; statistical significance does not establish a large clinical benefit or nerve repair.

What the cell study adds

Liu and colleagues exposed human umbilical vein endothelial cells to high glucose, then treated them with calcitriol, the active vitamin D hormone. Selected injury signals fell and viability and migration improved. Increasing a protein called TIPE1, tumour necrosis factor alpha-induced protein 8-like 1, opposed several responses. This supports investigation of a cellular pathway within endothelial function.

The experiment used three independent replicates, a large-vessel cell model and no reported matched osmotic control. Computer-predicted vitamin D receptor binding sites were not confirmed by direct promoter-binding experiments. A separate comparison of blood samples from people with and without complications was observational, not a supplementation trial.

Why the mechanism remains unresolved

The clinical trial did not measure TIPE1, and the cell experiment did not measure blood flow in a person. Neither directly tested metabolic flexibility, the ability to adapt fuel use, despite the relevance of metabolic stress to their questions. Changes observed at different biological levels cannot be assembled into a proven treatment pathway.

The findings support more rigorous research with clearer reporting and direct clinical outcomes. They do not establish an optimal supplement dose, general safety, improved nerve oxygenation or prevention of kidney, retinal or other diabetic complications. The high-dose regimen and achieved blood concentrations are study details, not recommendations.

Scientific sources

Karonova T, Stepanova A, Bystrova A, Jude EB. High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients. Nutrients. 2020;12:2518. DOI: 10.3390/nu12092518. PMID: 32825324. The complete principal paper, participant flow diagram and three tables were examined.

Liu Z, Sun H, Chen Y, He J, Zhu L, Yang B, Zhao W. High glucose-induced injury in human umbilical vein endothelial cells is alleviated by vitamin D supplementation through downregulation of TIPE1. Diabetology & Metabolic Syndrome. 2024;16:18. DOI: 10.1186/s13098-024-01264-5. PMID: 38216955. The complete principal paper, all six figures and clinical table were examined.

ClinicalTrials.gov. High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy. NCT04377399. First posted 6 May 2020, after the recorded study completion. This is the registration for the Karonova trial, not an independent efficacy study.

Related reading

Original sources

Source

High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients

Published in Nutrients (2020).

Publication details

Karonova T, Stepanova A, Bystrova A, Jude EB. High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients. Nutrients. 2020;12:2518. DOI: 10.3390/nu12092518. PMID: 32825324. The complete principal paper, participant flow diagram and three tables were examined.

Read more →
Source

High glucose-induced injury in human umbilical vein endothelial cells is alleviated by vitamin D supplementation through downregulation of TIPE1

Published in Diabetology & Metabolic Syndrome (2024).

Publication details

Liu Z, Sun H, Chen Y, He J, Zhu L, Yang B, Zhao W. High glucose-induced injury in human umbilical vein endothelial cells is alleviated by vitamin D supplementation through downregulation of TIPE1. Diabetology & Metabolic Syndrome. 2024;16:18. DOI: 10.1186/s13098-024-01264-5. PMID: 38216955. The complete principal paper, all six figures and clinical table were examined.

Read more →
Trial registry

High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy

ClinicalTrials.gov. High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy.

Publication details

ClinicalTrials.gov. High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy. NCT04377399. First posted 6 May 2020, after the recorded study completion. This is the registration for the Karonova trial, not an independent efficacy study.

Read more →